USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Surveyor Endonuclease Adaptor-Ligated Libraries for Genomic…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
90954
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
0839635
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
TRANSGENOMIC, INC.
12325 Emmet Street Omaha, NE 68164-4268
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: SBIR Phase I: Surveyor Endonuclease Adaptor-Ligated Libraries for Genomic Mutation Analysis
Agency: NSF
Contract: 0839635
Award Amount: $99,353.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project develops a novel process allowing rapid and cost-effective analysis of genetic variation between test and known, control genomes. The method, known as SEAL, will allow researchers to construct DNA libraries containing only these variations. This would be a breakthrough in technology as whole genome sequencing produces vast amounts of redundant data representing the test genome?s regions that are identical to the control genome. Using current sequencing technologies this redundant data imposes high generation and analysis costs without contributing any new information. This project will demonstrate the method?s feasibility by developing robust bacterial genome analysis applications. Each step of the multi-staged method will be tested to find optimal conditions. Phase II aims will be developing more complex human genomic applications. The broader impacts of this research are on how DNA sequencing is performed and DNA variation is assessed. Research areas impacted include: pharmacogenomic assessment for personalized medicine diagnostics, notably in cancer treatment; simpler, less data-intensive methods to collect the genetic variation information required for understanding complex diseases, such as diabetes and cardiovascular disease, and tools for discovery of new antibiotics for drug-resistant pathogens. The commercial value will be a dramatic decrease in the cost and time of genome sequencing, identification of biomarkers associated with appropriate treatments and decreased requirements for very high cost sequencing equipment.

Principal Investigator:

Gary F. Gerard
BS
2406312001
ggerard@transgenomic.com

Business Contact:

Gary F. Gerard
BS
2406312001
ggerard@transgenomic.com
Small Business Information at Submission:

Transgenomic, Inc.
12325 Emmet Street Omaha, NE 68164

EIN/Tax ID: 911789357
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No